JBT Marel (NYSE:JBTM) Posts Q2 CY2026 Sales In Line With Estimates but Non

JBT Marel (NYSE:JBTM) reported Q2 CY2026 sales of $981 million, up 4.9% year on year and in line with Wall Street estimates, according to the company. Full-year revenue guidance was $4.03 billion at the midpoint, near consensus. Adjusted Q2 EPS was $1.95, 3.4% below analysts’ consensus, and the company guided full-year EPS from $7.45 to $8.93.

Original reporting
Published Aug 3, 2026, 10:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 11:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JBT Marel (NYSE:JBTM) Posts Q2 CY2026 Sales In Line With Estimates but Non — source image
Decision brief

The 30-second read

$JBTMBearishMed
01

Why it matters

For trading, the key tension is revenue meeting estimates while adjusted EPS underperforms consensus and full-year EPS guidance is described as missing, which can drive near-term valuation pressure even if top-line looks stable.

02

Market read

Investors get a fresh datapoint on Q2 revenue and adjusted EPS versus consensus, plus full-year revenue guidance and an implied EPS trajectory, explaining the immediate selloff.

03

What to watch

The article highlights operating margin stability around 4.7% in Q2 and operating margin averaging 6.8% over five years; traders may re-rate if margins stabilize or improve even with slower revenue growth.

Relevance 7/10Novelty 6/10Timing: post-Q2 earnings reaction, reported guidance and consensus comparisons

Background

The piece frames JBT Marel’s Q2 CY2026 results versus Wall Street expectations, including revenue growth, operating margin, and adjusted EPS versus consensus.

Company-level read

Ticker impact

$JBTMBearishMedium confidence
Context

JBT Marel reported Q2 CY2026 sales of $981M in line with estimates, but adjusted EPS of $1.95 missed consensus and FY revenue guidance was near estimates.

Expected impact

Bias toward continued post-earnings weakness or choppy trading until investors focus on margin and EPS trajectory.

Evidence & confidence

The article cites a Q2 adjusted EPS miss versus consensus, FY EPS expected to rise from $7.45 to $8.93, and notes the stock traded down 3.7% immediately after reporting, implying the market weighed earnings quality more than revenue.

Market effects

Signals to industrial equipment peers that demand may be steady but earnings leverage is harder to sustain, especially when EPS misses despite revenue stability.

Primarily US industrials sentiment, with limited direct regional spillover beyond industrial equipment investors.

Modest global read-through for food processing and aviation equipment demand expectations, but no cross-border deal or regulatory catalyst mentioned.

Counterpoint

Revenue was in line and FY revenue guidance is close to estimates, so the EPS miss could be a temporary timing or cost-structure issue rather than a durable demand problem.

Key entities

  • JBT Marel

    Food processing and aviation equipment manufacturer reporting Q2 CY2026 sales and adjusted EPS, plus full-year revenue guidance.

Related articles

$JBTMMed

JBT Marel (JBTM) Q2 2026 Earnings Call Transcript

JBT Marel (JBTM) reported Q2 2026 revenue of $981 million, up 5% YoY, with Protein Solutions at $467 million (+11%) and Prepared Food and Beverage Solutions at $514 million (flat). Adjusted EBITDA was $168 million (17.1% margin) and adjusted diluted EPS was $1.95. Inbound orders were $1.03 billion and backlog $1.54 billion. Full-year revenue guidance is $3.99B to $4.065B.

$JBTMMed

JBT Marel Q2 Earnings Call Highlights

JBT Marel (NYSE:JBTM) said Q2 revenue was about $20M below expectations, mainly from delayed logistics shipments and production inefficiencies from facility moves, and that the deferral reduced quarterly EBITDA by about $5M to $6M. It reported $17M in IEEPA tariff refunds, offset by higher tariff expense and other costs. The company forecast Q3 organic revenue growth of 2% to 4% and maintained full-year guidance, targeting 2028 20% adjusted EBITDA margin.

Med

JBT Marel Corporation Q2 2026 Earnings Call Summary

JBT Marel reported a Q2 2026 earnings call with third straight quarter of orders above $1B, driven by double-digit Prepared Food and Beverage growth and poultry investment. Prepared Food revenue was flat due to logistics and production inefficiencies from a ~15% global footprint reduction. Full-year 2026 guidance was maintained; 2028 targets include $25M-$30M cost synergies and 20% adjusted EBITDA margin. A $200M buyback was authorized.

$JBTMMedAI 8/10

Why JBT Marel (JBTM) Stock Is Nosediving

JBT Marel (JBTM) shares fell about 7.1% after Q2 adjusted EPS of $1.95 missed the $2.02 consensus. The company also cut full-year adjusted EPS guidance to $8.10 at the midpoint, down 1.8% from prior outlook. The article notes JBTM is volatile and highlights broader industrial and oil-rate sensitivity.

$JBTMMed

JBT MAREL Corp (JBTM): Results of Operations and Financial Condition

JBT MAREL Corp (JBTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release JBT Marel Corporation 333 West Wacker Drive Suite 3400 Chicago, IL 60606 JBT Marel Corporation Reports Second Quarter 2026 Results Second Quarter 2026 Highlights: ◦ Continued strong demand with orders exceeding $1 billion; revenue was $981 million, resul

$NAMed

Nano Labs Ltd (NA): Financial results for H1 2026

Nano Labs Ltd (NA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nano Labs Announces First Half of 2026 Financial Results HONG KONG, August 28, 2026 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure provider and crypto treasury company, today announced its unaudit